Skip to main content

3-FMA Facts

Stimulant; Substituted amphetamine; Dopamine releasing agent

Description

3-FMA (3-fluoromethamphetamine) is a synthetic stimulant of the phenethylamine class. It works by flooding synapses with dopamine, norepinephrine, and serotonin,[1] producing stimulation, energy, and motivation.

Subjective effects include cognitive stimulation, physical energy, euphoria, enhanced sociability, and increased motivation. The experience is functional and task-oriented — closer to a productivity tool than the empathogenic warmth of more serotonergic stimulants,[2] and less intense than methamphetamine overall.

3-FMA carries abuse liability comparable to methamphetamine in rodent models,[3] and high doses damage dopamine-producing brain regions through oxidative stress.[4] Combining it with MAOIs can trigger fatal serotonin overload or dangerous blood pressure spikes.

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight10 – 20 mgCommon20 – 35 mgStrong35 – 50 mgHeavy50+ mg

Starts in 20 – 60 minLasts 3 – 7 hoursAfter-effects 6 – 12 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
High
Withdrawal
Mild
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
14 days
Carries over to
amphetamine; methamphetamine; MDMA; other monoamine releasing agents

Effectslikely at a common dose

Body
Appetite suppression; Stimulation; Wakefulness; +20 possible, including Insomnia, Vasoconstriction, Dehydration sensation
Thinking
none likely · 18 possible, including Compulsive redosing urge, Cognitive dysphoria
Feeling
none likely · 9 possible, including Anxiety, Dysphoria, Depression
Self
none likely · 9 possible, including Craving, Compulsive repetitive behavior, Ego inflation
Awareness
Sustained attention (vicara); +1 possible

Who shouldn't take it

Absolute
Cardiovascular disease; Uncontrolled hyperthyroidism; MAOIs (all classes)
Relative
Seizure disorders; Psychotic disorders; Bipolar disorder; Hepatic impairment; Pregnancy and lactation; CYP2D6 poor metabolizer status; SSRIs/SNRIs; Lithium; Other stimulants

Combinations60 recorded

Lethal (1)
MAOIs
Dangerous (33)
Anticholinergics; Atypical antipsychotics; Caffeine; Dopamine agonists; Ephedrine, Pseudoephedrine; Local anesthetics; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; Psychedelics; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Alpha-2 adrenergic receptor antagonist; Antihistamines; Antipsychotics; Buspirone; Clonidine, Guanfacine; DXM; GHB, Baclofen; GHB, GBL; and 9 more, see full page
Caution (23)
See full page: psychedex.org/substances/3-fma
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines — Annual Review of Pharmacology and Toxicology PMID:17209801
  2. [2]
    ^Rickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2014.12.012
  3. [3]
    ^Ryu IS, Yoon SS, Choi MJ, Lee YE, Kim JS, Kim WH, Cheong JH, Kim HJ, Jang CG, Lee YS, Steffensen SC, Ka M, Woo DH, Jang EY, Seo JW (2020) The potent psychomotor, rewarding and reinforcing properties of 3-fluoromethamphetamine in rodents. — Addiction Biology doi:10.1111/adb.12846
  4. [4]
    ^Nguyen PT, Shin EJ, Dang DK, Tran HQ, Jang CG, Jeong JH, Lee YJ, Lee HJ, Lee YS, Yamada K, Nabeshima T, Kim HC (2018) Role of dopamine D1 receptor in 3-fluoromethamphetamine-induced neurotoxicity in mice. — Neurochemistry International doi:10.1016/j.neuint.2017.11.017
Print version
Report an issue